The cancer stem cell (CSC) hypothesis suggests that neoplastic clones are maintained exclusively by a rare fraction of cells with stem cell proprieties. Like normal stem cells, these rare CSCs possess the extensive proliferative and self-renewal potential necessary to create a new tumor and generate a hierarchy of phenotypically diverse downstream cells, which are successively more limited in these properties. On the other hand, as in normal tissue stem cells, CSCs should display the ability to undergo a broad range of differentiation events. The transdifferentiative capacity of normal stem cells is a common property of CSCs. As an example, melanoma CSCs, like all the other CSCs, may transdifferentiate into diverse phenotypes [1] , express neurogenic, angiogenic, vasculogenic and also lymphatic markers [1] , and are able to organise a pseudovascular network in a physiological assay such as aorta ring [2] . Additional work demonstrated that more aggressive melanoma cells can revert to an undifferentiated, embryonic-like phenotype [3] . Moreover, aggressive melanoma cells express endothelium-associated genes and can form extracellular matrix rich vasculogenic like networks in three dimensional cultures [4] [5] [6] [7] [8] [9] [10] . Microarray analysis confirmed a genetic reversion of aggressive melanoma cells to an undifferentiated embryonic-like phenotype [11] [12] [13] . More recently, glioblastoma stem-like cells were observed to transdifferentiate into endothelial cells [14] [15] [16] . All together, the capability to transdifferentiate appears to be a way for the cells to become more plastic and adapt to different and adverse environmental conditions. Vasculogenic mimicry was first described by the unique ability of aggressive melanoma cells to express an endothelial phenotype and to form vessel-like networks in three dimensional cultures, "mimicking" the pattern of embryonic vascular networks and recapitulating the patterned networks seen in patients with aggressive tumors correlated with poor prognosis [13] . In fact, the word ''vasculogenic'' was selected to indicate the generation of the pathway de novo and ''mimicry'' was used because the tumour uses cell pathways for transporting fluid in tissues that were clearly not blood vessels. Additional studies have reported vasculogenic mimicry in several other tumor types, including breast, prostate, ovarian, chorio-, lung carcinomas, synovial-, rhabdomyosarcoma, Ewing sarcomas and paeochromocytoma [17] . I believe that two important aspects must be emphasised: the first one is to develop new strategies targeting CSC subpopulations. The use of antiangiogenic drugs in combination with drugs acting on specific targets of CSC subpopulations might open up interesting new therapeutic perspectives. The second, novel aspect, is to use AQP1 as a target. According to the model proposed by Verkman and collaborators, AQP1 drives water influx, facilitating lamellipodia extension and cell migration [18] . While investigating the possible connection between AQP1 and cytoskeleton, our group recently showed that such a water channel through Lin7/beta catenin is expressed both by human endothelium and melanoma cells and affects the organization of the cytoskeleton [19] . We also proposed a model where AQP1 appears to be a critical scaffold for plasma-membrane associated multiprotein-complex to stabilise the cytoskeleton [20] . By combining Verkman's and our model, we suggested that AQP1 is deeply involved in the lamellipodium organisation because, in presence of local osmotic gradients like as at the tip of lamelllipodium, water is driven inside through AQP(s) leading to the disruption of scaffold proteins which are degraded through proteasoma (Lin7/beta catenin) [20] . The effect on the cell is the cleavage of actin [20] .
AQP1 might be a useful target for a combined melanoma therapy for two main reasons. Firstly, in melanoma the expression of AQP1 might be crucial for the growth of the tumor through its involvement in the vasculogenic/angiogenic pathways. In fact, AQP1 plays a crucial role in the capability of the cells (endothelial or melanoma cells) to sprout in knocked out animals or in cells where AQP1 has been silenced by siRNA. Secondly, AQP1 targeting might contribute to target quiescent CSCs that may be resistant to conventional therapy.
